A Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies.

Trial Profile

A Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2015

At a glance

  • Drugs Ibandronic acid; Ibandronic acid
  • Indications Bladder cancer; Cancer metastases; Gastrointestinal cancer; Haematological malignancies; Lung cancer; Multiple myeloma; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 27 Sep 2015 New Source identified and integrated (ClinicalTrials.gov:NCT02561039).
    • 23 Mar 2008 Status changed from in progress to completed, from Roche record.
    • 20 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top